ATN-161 trifluoroacetate salt

Research use only, not for human use.

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model.The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy.

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model.The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy. In addition, combination therapy leads to a significant increase of apoptotic (TUNEL-positive) tumor cells, whereas single-agent therapy does not increase in TUNEL-positive tumor cells. ATN-161 treatment leads to a significant reduction in EC number (21% decrease) after a 48 hr incubation time compared to control. ATN-161 inhibits VEGF-induced migration and capillary tube formation in hCECs, but did not inhibit proliferation. ATN-161 decreases the number of cells migrating in response to VEGF in a dose-dependent manner starting at 100 nM (P<0.001 vs. VEGF group).The preliminary experiments with α5β1-negative human colon cancer xenografts (HT29) show that treatment with ATN-161 significantly reduces tumor weight and vessel density. Injection of ATN-161 after laser photocoagulation inhibits choroidal neovascularization (CNV) leakage and neovascularization to an extent similar to AF564.

ATN-161 TFA salt

Cell Cycle/DNA Damage

Integrin

Integrin α5β1

Cancer

Brain and Central Nervous System Tumors

904763-27-5

711.67

C25H36F3N9O10S

>98% (HPLC)

DMSO:1 mg/mL (1.41 mM; Need ultrasonic)

OC(=O)C(F)(F)F.CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O

——

(-20℃)

With Ice Pack

≥ 2 years